Orum Therapeutics raised roughly $100 million (146 billion Korean won) to advance a pipeline that fuses antibody targeting with protein‑degrading payloads — ‘degrader‑antibody conjugates’ — and to accelerate its lead AML candidate ORM‑1153 toward a clinical entry slated as early as late‑2026. Orum said it has shelved an earlier HER2 program after observing liver toxicity but will focus resources on CD123‑targeting programs for acute myeloid leukemia and follow collateral preclinical assets. The company maintains collaborations with Bristol Myers Squibb and Vertex that extend its development reach. Investors flagged the strategic pivot from ADC toxins to degrader payloads as an attempt to overcome resistance mechanisms seen with conventional ADCs; safety and payload delivery will be critical milestones for the platform’s clinical viability.